Drugs known as GLP-1 receptor agonists have become some of the most talked-about medicines in recent years.
Medicines such as semaglutide and liraglutide were first developed to help people with type 2 diabetes control their blood sugar.
Later, they became famous because they also help many people lose weight. Millions of people around the world now use these medications.
As scientists continue to study these drugs, they are discovering that their effects may go far beyond diabetes and obesity. New research suggests that these medicines may also affect the immune system and reduce inflammation, raising the possibility that they could one day help treat some chronic skin diseases.
The new findings come from a review published in the journal Pharmaceutics by researchers at Wroclaw Medical University in Poland. The researchers examined studies looking at whether GLP-1 receptor agonists could be useful in dermatology, the branch of medicine that focuses on skin diseases.
Interest in these drugs began with simple observations made by doctors. Some patients who were taking GLP-1 medicines for diabetes or obesity noticed something unexpected. Their skin conditions, particularly psoriasis, seemed to improve.
At first, these cases appeared to be isolated events. Doctors wondered whether the improvements simply happened because patients lost weight and became healthier overall.
Over time, scientists started asking a more interesting question. Could these drugs be directly affecting the biological processes that cause skin diseases?
A major breakthrough came when researchers discovered that GLP-1 receptors are not found only in the pancreas and digestive system. They are also present on cells involved in the immune system. This finding suggested that the medicines might directly influence inflammation throughout the body.
Many common skin diseases involve long-term inflammation. Psoriasis, atopic dermatitis, and hidradenitis suppurativa may look very different from one another, but they share an important feature.
In all of these conditions, the immune system remains active for long periods and continues to trigger inflammation. This ongoing inflammation damages tissues and causes symptoms to return again and again.
Research suggests that GLP-1 receptor agonists may affect several kinds of immune cells. They may also reduce the production of inflammatory substances that are known to play major roles in skin disease. This anti-inflammatory effect has become one of the most exciting aspects of these medicines.
Psoriasis is currently the skin disease with the most available evidence. Psoriasis affects around 2 to 3 percent of the world’s population. It causes red, thick, scaly patches on the skin and can greatly affect quality of life. Scientists now understand that psoriasis is not just a skin condition. It is linked to obesity, insulin resistance, type 2 diabetes, and heart disease.
Because of these connections, GLP-1 drugs may be particularly useful for some people with psoriasis. Several studies have reported improvements in psoriasis severity after treatment with liraglutide or semaglutide.
However, researchers still do not know exactly how much of the benefit comes from reducing inflammation and how much results from weight loss and improved metabolic health.
Researchers are also becoming interested in atopic dermatitis, often called eczema. This condition causes itchy, inflamed skin and is linked to problems with the skin barrier and the immune system.
Early experimental studies suggest that GLP-1 medicines may help control inflammation and support the repair of damaged tissues. However, there is still very little clinical evidence in patients.
Scientists have also found signs that these drugs may improve blood flow, support tissue repair, and speed wound healing. This could be especially important for people with diabetes, who often develop wounds that heal slowly and can become serious medical problems.
Despite the promising findings, experts remain cautious. The current evidence is still limited, and these drugs should not be considered replacements for modern treatments for psoriasis or eczema. Instead, they may eventually become additional treatment options, especially for patients who also have obesity or diabetes.
The review highlights how diseases affecting different parts of the body are often connected. Skin health, metabolism, inflammation, and cardiovascular health may influence one another in complex ways. Medicines originally designed for diabetes may eventually become useful tools in entirely different areas of medicine.
Analysis of the findings suggests that the research is exciting but still at an early stage. Most of the evidence comes from observations and small studies rather than large clinical trials. More research is needed before doctors know exactly which patients may benefit and how these drugs should be used.
Even so, the findings open an interesting new direction in medicine and show that treatments developed for one disease sometimes hold unexpected promise for many others.
If you care about skin health, please read studies about top signs of diabetic skin disease, and Mediterranean diet could help lower the skin cancer risk.
For more health information, please see recent studies about eating fish linked to higher risk of skin cancer, and results showing how to combat the effects of aging on your skin.
Source: Wroclaw Medical University.
